01
GLP-1
GLP-1 signalling affects satiety, gastric emptying and glucose-dependent insulin response.
GLP-1/glucagon receptor dual agonist
Survodutide
GLP-1 · Glucagon
Survodutide (BI 456906) combines GLP-1 and glucagon receptor agonism and is being studied for obesity and liver disease. The balance between weight reduction, liver effects and gastrointestinal tolerability is central to phase 3 development.
2Overview
1× / wkReference frequency
DataPhase 2 and reported phase 3
Research status
Phase 3 development
SURVODUTIDE10 MG
01 · Overview
What is Survodutide?
Survodutide (BI 456906) combines GLP-1 and glucagon receptor agonism and is being studied for obesity and liver disease. The balance between weight reduction, liver effects and gastrointestinal tolerability is central to phase 3 development.
Research route, formulation and population determine what a result actually means.
02
Glucagon
Glucagon-receptor signalling affects liver metabolism and energy expenditure.
02 · Research
What do the studies show?
Phase 2 and reported phase 3. Educational information. Not diagnosis, treatment or use advice.
18.7%
Phase 2Obesity trial at week 46
In phase 2, the highest planned dose achieved large mean weight reduction; discontinuations and gastrointestinal adverse effects were relevant.
Phase 3
Phase 3Larger confirmatory trials
Recent phase 3 publications confirm efficacy in obesity while also examining liver fat and metabolic complications.
03 · DATA
Peptide and product specifications
Checked identity data for this research compound or blend.
SurvodutidePeptide and product specifications
Development code
BI 456906
Developer
Boehringer Ingelheim / Zealand Pharma
Molecular formula
C₁₉₂H₂₈₉N₄₇O₆₁
Molecular weight
4231.69 Da
CAS number
2805997-46-8
Amino-acid sequence / components
His-1-aminocyclobutanecarboxyl-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-Glu-Arg-Ala-Ala-Lys-Asp-Phe-Ile-Lys(side-chain)-Trp-Leu-Glu-Ser-Ala-NH₂
Amino-acid count
29 in de hoofdketen + een 7-residu linker/zijtak
Modified residues
C18 diacid/γ-glutamate-Gly-Ser-Gly-Ser-Gly-Gly side chain at Lys²⁴; C-terminal alaninamide
Purity
Batch-specific — confirm identity and purity with the Velora COA
Reference diluent
Formulation- and batch-specific; there is no universal diluent for every research compound
Unreconstituted-material storage
Follow the accompanying COA, product label and validated stability data
These are compound references, not a batch certificate. Purity and identity of a specific Velora batch must be confirmed by its accompanying COA and laboratory report.
Official USAN identity document ↗04 · Calculator
Reconstitution and U-100 conversion
This module only converts concentration and volume. Inputs are not recommendations or individual dosing advice.
Calculator
Once weekly in clinical trials
1
2
3
4
Draw to
0 units
0.00 mL
SURVODUTIDE
10 MG
Concentration—
Per unit—
Complete amounts—
Calculated duration—
LAB · RECONSTITUTION
How to reconstitute Survodutide for laboratory research
A visual workflow for controlled laboratory reconstitution. Always follow the product label, COA and a validated protocol.
Clean
Disinfect the rubber closures of both vials and allow them to dry.
Measure diluent
Withdraw only the diluent validated for the specific compound.
Add slowly
Let the liquid run slowly down the inside wall of the vial.
Swirl gently
Do not shake; rotate gently until the material has dissolved.
Store per protocol
Follow the product label, COA and validated stability data.
Important checks before and after reconstitution
Check the product
First confirm that the product is a lyophilised vial. Prefilled pens and ready-to-use solutions do not require reconstitution. Check the label, COA and specified diluent.
Use clean, sterile technique
Wash your hands, clean the work surface and use new sterile equipment for every procedure. Clean both rubber closures with separate alcohol swabs and let them dry completely.
Concentration, not total amount
The volume of liquid added changes the concentration in mg per mL, but not the total amount of research compound in the vial. Use the calculator to check this in advance.
Inspect and label
Check for unexpected discoloration, cloudiness or visible particles. Record the compound, concentration and reconstitution date. Storage time and temperature are product-specific; a fixed 28-day rule does not apply to every compound.
General reconstitution volumes listed by the source
General examples, not a product-specific protocol. The chosen volume determines concentration; always check the label, COA and calculator.
| Vial strength | Commonly listed volume |
|---|---|
| 2 mg | 1–2 mL |
| 5 mg | 2–3 mL |
| 6 mg | 2–3 mL |
| 10 mg | 2–4 mL |
| 15 mg | 3–5 mL |
| 20 mg | 4–8 mL |
Practical background source: Free Medical Journals — Complete Step-by-Step Guide to Peptide Reconstitution, accessed July 2026. This is a secondary educational source; the product label, COA and validated stability data remain authoritative.
05 · Safety and limitations
Safety and limitations
Research route, formulation and population determine what a result actually means.
What is known
- Visible research claims use primary or official sources.
- The calculator is arithmetic and does not turn a study amount into medical advice.
- A registered medicine and a research vial are not automatically equivalent.
What remains uncertain
- Many products lack long-term safety data and independent replication.
- Animal and cell findings do not predict a safe human dose.
- Stability depends on formulation, pH, sterility, light, temperature and packaging.
Status: Phase 3 development. Educational information. Not diagnosis, treatment or use advice.
06 · FAQ
Frequently asked questions
Survodutide (BI 456906) combines GLP-1 and glucagon receptor agonism and is being studied for obesity and liver disease. The balance between weight reduction, liver effects and gastrointestinal tolerability is central to phase 3 development.
In phase 2, the highest planned dose achieved large mean weight reduction; discontinuations and gastrointestinal adverse effects were relevant. Recent phase 3 publications confirm efficacy in obesity while also examining liver fat and metabolic complications.
No. It performs arithmetic conversions only. Medical decisions belong with a licensed healthcare professional.
The curve follows the agreed storage model and is not a laboratory result.
2–8 °C. Protect from light and repeated freeze-thaw cycles.